MAZE
Maze Therapeutics Inc
NASDAQ · Pharmaceuticals
$45.03
+1.08 (+2.46%)
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 184.11M | 546.10M | 525.77M | 523.61M |
| Net Income | 20.20M | 109.70M | 88.79M | 91.93M |
| EPS | — | — | — | — |
| Profit Margin | 11.0% | 20.1% | 16.9% | 17.6% |
| Rev Growth | — | +21.9% | +7.3% | -7.2% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 615.27M | 505.54M | 518.26M |
| Total Equity | — | 833.25M | 765.68M | 754.51M |
| D/E Ratio | — | 0.74 | 0.66 | 0.69 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 66.92M | 173.82M | 160.69M | 151.47M |
| Free Cash Flow | — | 65.89M | 67.30M | 41.13M |